Insider Trading Alert - DGX, CELG And HPQ Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, March 5, 2014, 233 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $57.59 to $85,937,500.00.

Highlighted Stocks Traded by Insiders:

Quest Diagnostics (DGX) - FREE Research Report

Prevoznik Michael E who is SVP & General Counsel at Quest Diagnostics sold 778 shares at $53.00 on March 5, 2014. Following this transaction, the SVP & General Counsel owned 43,212 shares meaning that the stake was reduced by 1.77% with the 778-share transaction.

The shares most recently traded at $52.59, down $0.41, or 0.78% since the insider transaction. Historical insider transactions for Quest Diagnostics go as follows:

  • 4-Week # shares bought: 5,000
  • 4-Week # shares sold: 3,687
  • 12-Week # shares bought: 5,000
  • 12-Week # shares sold: 3,687
  • 24-Week # shares bought: 5,000
  • 24-Week # shares sold: 6,345

The average volume for Quest Diagnostics has been 2.6 million shares per day over the past 30 days. Quest Diagnostics has a market cap of $7.5 billion and is part of the health care sector and health services industry. Shares are down 2.39% year-to-date as of the close of trading on Wednesday.

Quest Diagnostics Incorporated provides diagnostic testing information services in the United States and internationally. The company operates in two businesses, Diagnostic Information Services and Diagnostic Solutions. The stock currently has a dividend yield of 2.53%. The company has a P/E ratio of 9.8. Currently there are 2 analysts that rate Quest Diagnostics a buy, 4 analysts rate it a sell, and 12 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on DGX - FREE

TheStreet Quant Ratings rates Quest Diagnostics as a buy. The company's strengths can be seen in multiple areas, such as its compelling growth in net income, notable return on equity, largely solid financial position with reasonable debt levels by most measures, expanding profit margins and growth in earnings per share. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Quest Diagnostics Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Celgene Corporation (CELG) - FREE Research Report

Karsen Perry A who is see remarks at Celgene Corporation sold 2,408 shares at $159.05 on March 5, 2014. Following this transaction, the see remarks owned 25,960 shares meaning that the stake was reduced by 8.49% with the 2,408-share transaction.

The shares most recently traded at $160.89, up $1.84, or 1.14% since the insider transaction. Historical insider transactions for Celgene Corporation go as follows:

  • 24-Week # shares bought: 1,000

The average volume for Celgene Corporation has been 3.1 million shares per day over the past 30 days. Celgene Corporation has a market cap of $65.7 billion and is part of the health care sector and drugs industry. Shares are down 4.22% year-to-date as of the close of trading on Wednesday.

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies to treat cancer and immune-inflammatory related diseases in the United States and internationally. The company has a P/E ratio of 48.0. Currently there are 24 analysts that rate Celgene Corporation a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CELG - FREE

TheStreet Quant Ratings rates Celgene Corporation as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, notable return on equity, reasonable valuation levels, expanding profit margins and good cash flow from operations. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Celgene Corporation Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Hewlett-Packard (HPQ) - FREE Research Report

Ricci Jeff T who is VP, Controller & PAO at Hewlett-Packard sold 3,729 shares at $29.97 on March 5, 2014. Following this transaction, the VP, Controller & PAO owned 967 shares meaning that the stake was reduced by 79.41% with the 3,729-share transaction.

The shares most recently traded at $30.00, up $0.03, or 0.1% since the insider transaction. Historical insider transactions for Hewlett-Packard go as follows:

  • 4-Week # shares sold: 31,253
  • 12-Week # shares sold: 35,018
  • 24-Week # shares sold: 47,018

The average volume for Hewlett-Packard has been 13.1 million shares per day over the past 30 days. Hewlett-Packard has a market cap of $57.3 billion and is part of the technology sector and computer hardware industry. Shares are up 7.65% year-to-date as of the close of trading on Wednesday.

Hewlett-Packard Company, together with its subsidiaries, provides products, technologies, software, solutions, and services to individual consumers, small-and medium-sized businesses (SMBs), and large enterprises, including customers in the government, health, and education sectors worldwide. The stock currently has a dividend yield of 1.93%. The company has a P/E ratio of 11.5. Currently there are 6 analysts that rate Hewlett-Packard a buy, 2 analysts rate it a sell, and 12 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on HPQ - FREE

TheStreet Quant Ratings rates Hewlett-Packard as a hold. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth and attractive valuation levels. However, as a counter to these strengths, we find that the company's profit margins have been poor overall. Get the full Hewlett-Packard Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null

More from Markets

Trump May Be More to Blame For Higher Oil Prices Than OPEC

Trump May Be More to Blame For Higher Oil Prices Than OPEC

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric

Week Ahead: Major Earnings on Tap as Wall Street Readies for Geopolitical Moves

Week Ahead: Major Earnings on Tap as Wall Street Readies for Geopolitical Moves

3 Hot Reads From TheStreet's Top Premium Columnists

3 Hot Reads From TheStreet's Top Premium Columnists

Video: How to Select Mutual Funds in Your 401(k)

Video: How to Select Mutual Funds in Your 401(k)